Literature DB >> 24692764

Steady-state serum phenytoin concentrations after nasogastric tube administration of immediate-release phenytoin tablets and extended-release phenytoin capsules: an open-label, crossover, clinical trial.

Duangchit Panomvana1, Napanan Khummuenwai1, Supasil Sra-Ium2, Somchai Towanabut3.   

Abstract

BACKGROUND: When phenytoin is prescribed for administration via nasogastric tube, immediate-release OR) phenytoin tablets are crushed before use and extended-release (ER) phenytoin capsules are opened and only the granules are used. However, it is unknown whether the same dose of these 2 different formulations will result in the same steady-state serum phenytoin concentration.
OBJECTIVE: The aim of this study was to determine whether ER phenytoin capsules can be used interchangeably with IR phenytoin tablets for prophylaxis of posttraumatic seizures.
METHODS: Inpatients at the neurosurgical ward at Prasat Neurological Institute, Bangkok, Thailand, between October 2004 and October 2005 were enrolled in the study. All patients were initially prescribed IR phenytoin tablets 300 mg/d as a maintenance dose for prophylaxis of posttraumatic seizures. The serum phenytoin concentration was measured after ≥5 days of treatment with IR phenytoin tablets 300 mg/d (two 50-mg tablets every 8 hours) that had been crushed before being administered concomitantly with a blenderized diet through the nasogastric tube. Without a washout period, the dosage form was changed to ER phenytoin capsules (three 100-mg capsules QD). The capsules were opened and the contents were administered concomitantly with the blenderized diet through the nasogastric tube for ≥5 days. The serum phenytoin concentration was again determined. The patients were closely monitored for seizures and adverse events (AEs).
RESULTS: Thirty-three patients enrolled in the study and 17 (10 women, 7 men; mean [SD] age, 62.94 [15.94] years [range, 18-89 years]) completed the study. The mean (SD) serum phenytoin concentrations after administration of phenytoin tablets and capsules were 6.03 (5.92) μg/mL and 3.80 (2.71) μg/mL, respectively (P = 0.019). The mean serum phenytoin concentrations, adjusted for low serum albumin concentrations after administration of tablets and capsules, were calculated and reported to be 10.33 (11.60) μg/mL and 6.28 (4.76) μg/mL, respectively (P = 0.035). The maximum phenytoin metabolic rate (Vmax) (assuming the substrate concentration at which the rate of metabolism is one half Vmax = 4 mg/L) after the administration of phenytoin tablets and capsules was 8.37 (2.42) mg/kg · d(-1) and 10.38 (6.48) mg/kg · d(-1), respectively. These values were not significantly different. All patients were seizure-free and no AEs were observed.
CONCLUSION: The steady-state serum phenytoin concentration was significantly lower with ER phenytoin capsules 300 mg/d than IR phenytoin tablets 300 mg/d administered via nasogastric feeding tube concomitantly administered with a blenderized diet in these neurosurgical patients. Key words: phenytoin nasogastric tube feeding extended-release capsule immediate-release tablet.

Entities:  

Year:  2007        PMID: 24692764      PMCID: PMC3969937          DOI: 10.1016/j.curtheres.2007.10.007

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  14 in total

1.  Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.

Authors:  M E Marvel; J S Bertino
Journal:  JPEN J Parenter Enteral Nutr       Date:  1991 May-Jun       Impact factor: 4.016

2.  Serum phenytoin levels of patients on gastrostomy tube feeding.

Authors:  B Faraji; P P Yu
Journal:  J Neurosci Nurs       Date:  1998-02       Impact factor: 1.230

3.  Recovery of phenytoin from an enteral nutrient formula.

Authors:  M A Hooks; R L Longe; A T Taylor; G E Francisco
Journal:  Am J Hosp Pharm       Date:  1986-03

4.  Interaction of oral phenytoin with enteral feedings.

Authors:  J J Saklad; R H Graves; W P Sharp
Journal:  JPEN J Parenter Enteral Nutr       Date:  1986 May-Jun       Impact factor: 4.016

5.  Effect of pH on the equilibrium dialysis of phenytoin suspension with and without enteral feeding formula.

Authors:  M Y Splinter; C F Seifert; J C Bradberry; Y H Tu; L V Allen
Journal:  JPEN J Parenter Enteral Nutr       Date:  1990 May-Jun       Impact factor: 4.016

6.  Interference of oral phenytoin absorption by continuous nasogastric feedings.

Authors:  L A Bauer
Journal:  Neurology       Date:  1982-05       Impact factor: 9.910

7.  Phenytoin absorption from tube feedings.

Authors:  G A Maynard; K M Jones; J R Guidry
Journal:  Arch Intern Med       Date:  1987-10

8.  Phenytoin absorption in volunteers receiving selected enteral feedings.

Authors:  J R Guidry; T F Eastwood; S C Curry
Journal:  West J Med       Date:  1989-06

9.  Phenytoin interaction with enteral feedings administered through nasogastric tubes.

Authors:  D Fleisher; N Sheth; J H Kou
Journal:  JPEN J Parenter Enteral Nutr       Date:  1990 Sep-Oct       Impact factor: 4.016

10.  Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.

Authors:  K K Doak; C E Haas; K J Dunnigan; R A Reiss; J R Reiser; J Huntress; J L Altavela
Journal:  Pharmacotherapy       Date:  1998 May-Jun       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.